6
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Role of CD8 + T cells in crescentic glomerulonephritis

      review-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Crescentic glomerulonephritis (cGN) comprises three main types according to the pathogenesis and immunofluorescence patterns: anti-glomerular basement membrane antibody cGN, vasculitis-associated cGN and post-infectious immune complex cGN. In this brief review of the immune-pathogenesis of cGN, the focus is mainly on the role of CD8 + T cells in the progression of cGN. Under control conditions, Bowman’s capsule (BC) provides a protected immunological niche by preventing access of cytotoxic CD8 + T cells to Bowman’s space and thereby podocytes. Even in experimental nephrotoxic nephritis, leukocytes accumulate around the glomeruli, but remain outside of BC, as long as the latter remains intact. However, when and where breaches in BC occur, the inflammatory cells can gain access to and destroy podocytes, thus converting cGN into rapidly progressive glomerulonephritis (RPGN). These conclusions also apply to human cGN, where biopsies show that loss of BC integrity is associated with RPGN and progression to end-stage kidney disease. We propose a two-hit hypothesis for the role of cytotoxic CD8 + T cells in the progression of cGN. The initial insult occurs in response to the immune complex formation or deposition, resulting in local capillary and podocyte injury (first hit). The injured podocytes release neo-epitopes, eventually causing T-cell activation and migration to the glomerulus. Upon generation of breaches in BC, macrophages and CD8 + T cells can now gain access to the glomerular space and destroy neo-epitope expressing podocytes (second hit), resulting in RPGN. While further investigation will be required to test this hypothesis, future therapeutic trials should consider targeting of CD8 + T cells in the therapy of progressive cGN.

          Related collections

          Author and article information

          Journal
          Nephrol Dial Transplant
          Nephrol. Dial. Transplant
          ndt
          Nephrology Dialysis Transplantation
          Oxford University Press
          0931-0509
          1460-2385
          April 2020
          16 March 2019
          16 March 2020
          : 35
          : 4
          : 564-572
          Affiliations
          [1 ] Division of Nephrology, Zhongshan Hospital, Xiamen University , Xiamen, Fujian province, China
          [2 ] Department of Medicine, Icahn School of Medicine at Mount Sinai , New York, NY, USA
          [3 ] Renal Section, James J. Peters VA Medical Center , Bronx, NY, USA
          Author notes
          Correspondence and offprint requests to: Detlef Schlondorff; E-mail: detlef.schlondorff@ 123456mssm.edu
          Article
          PMC7139212 PMC7139212 7139212 gfz043
          10.1093/ndt/gfz043
          7139212
          30879039
          c82792f2-c85a-4db1-81e5-9a98da9b9a6b
          © The Author(s) 2019. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.

          This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model ( https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)

          History
          : 15 November 2018
          : 09 January 2019
          Page count
          Pages: 9
          Funding
          Funded by: National Natural Science Foundation of China, DOI 10.13039/501100001809;
          Award ID: 81800637
          Funded by: Fujian Medical Technology Innovation Fund;
          Award ID: 2014-CXB-41
          Funded by: NIH, DOI 10.13039/100000002;
          Funded by: NIDDK, DOI 10.13039/100000062;
          Award ID: R01DK117913
          Funded by: Fujian Medical Technology Innovation Fund from China;
          Award ID: 2017-CXB-16
          Funded by: NIDDK, DOI 10.13039/100000062;
          Award ID: R01DK078897
          Award ID: R01DK088541
          Award ID: P01DK56492
          Funded by: VA Merit Award;
          Award ID: IBX000345C
          Categories
          Reviews

          ANCA,crescentic glomerulonephritis,glomerulonephritis podocytes,membranoproliferative,immunology

          Comments

          Comment on this article